Regulatory Affairs

Clinical Trials Drug Pricing Drug Approval Health Equity HIV/AIDS FDA Approval Infectious Diseases Cost Analysis

FDA to Decide on Twice-Yearly HIV Preventive Drug Lenacapavir

Generic manufacturers are set to produce lenacapavir for as little as $25 per patient annually